Publications of Interest

Sawicki, SM, Hernandez C, Laiteerapong N, Zahradnik EK. The use of dispensary-obtained tetrahydrocannabinol as a treatment for neuropsychiatric symptoms of dementia. J Clin Psychiatry. 2023 84(6):23m14791 10.4088/JCP.23m14791.

Bidwell LC, Karoly HC, Torres MO, Master A, Bryan AD, Hutchison KE. A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment. Psychopharmacology. 2022 Feb;239(2):385-397. doi: 10.1007/s00213-021-06007-2.

Lichenstein SD, Manco N, Cope LM, Egbo L, Garrison KA, Hardee J, Hillmer AT, Reeder K, Stern EF, Worhunsky P, Yip SW. Systematic review of structural and functional neuroimaging studies of cannabis use in adolescence and emerging adulthood: evidence from 90 studies and 9441 participants. Neuropsychopharmacology. 2022 Apr;47(5):1000-1028. doi: 10.1038/s41386-021-01226-9

Lorenzetti V, Kowalczyk M, Duehlmeyer L, Greenwood LM, Chye Y, Yücel M, Whittle S, Roberts CA. Brain Anatomical Alterations in Young Cannabis Users: Is it All Hype? A Meta-Analysis of Structural Neuroimaging Studies. Cannabis Cannabinoid Res. 2022 Apr 19. doi: 10.1089/can.2021.0099

Schwabe AL, Hansen CJ, Hyslop RM, McGlaughlin ME. Comparative Genetic Structure of Cannabis sativa Including Federally Produced, Wild Collected, and Cultivated Samples. Front Plant Sci. 2021 Sept 29. doi: 10.3389/fpls.2021.675770.

Shi Y, Liccardo Pacula R. Assessment of Recreational Cannabis Dispensaries' Compliance With Underage Access and Marketing Restrictions in California. JAMA Pediatrics. 2021;175(11):1178-1180. DOI: 10.1001/jamapediatrics.2021.2508

Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA. 2020 Dec 1;324(21):2177-2186. doi: 10.1001/jama.2020.21218

The Legalization of Marijuana in Colorado: The Impact. Rocky Mountain High Intensity Drug Trafficking Area. (2020, September). 

Zarrabi AJ, Frediani JK, Levy JM. The State of Cannabis Research Legislation in 2020. New England Journal of Medicine. 2020 May 14;382(20):1876-1877. doi: 10.1056/NEJMp2003095.

Crowder L. The rapid evolution of UC cannabis research. California Agriculture. 2019 Sept 73(3):106-112.

Moreau M, Ibeh U, Decosmo K, Bih N, Yasmin-Karim S, Toyang N, Lowe H, Ngwa W. Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer. Front Oncol. 2019 Jul 23;9:660. doi: 10.3389/fonc.2019.00660. eCollection 2019.

Nguyen JD, Grant Y, Creehan KM, Hwang CS, Vandewater SA, Janda KD, Cole M, Taffe MA. Δ9-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions. Neuropharmacology. 2019 Jun;151:127-135. doi: 10.1016/j.neuropharm.2019.04.010.

Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, Lintzeris N, Khor KE, Farrell M, Smith A, Le Foll B. Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology. 2017 Aug;42(9):1752-1765. doi: 10.1038/npp.2017.51.

Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, Nielsen S, Cohen M, Chan G, Mattick RP, Blyth F, Shanahan M, Dobbins T, Farrell M, Degenhardt L. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018 Jul;3(7):e341-e350. doi: 10.1016/S2468-2667(18)30110-5.

Campbell G, Hall W, Nielsen S. What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. Int Rev Psychiatry. 2018 Oct;30(5):91-106. doi: 10.1080/09540261.2018.1509842.

Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, Rodriguez V, Jongsma HE, Ferraro L, La Cascia C, La Barbera D, Tarricone I, Berardi D, Szöke A, Arango C, Tortelli A, Velthorst E, Bernardo M, Del-Ben CM, Menezes PR, Selten JP, Jones PB, Kirkbride JB, Rutten BP, de Haan L, Sham PC, van Os J, Lewis CM, Lynskey M, Morgan C, Murray RM; EU-GEI WP2 Group. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019 May;6(5):427-436. doi: 10.1016/S2215-0366(19)30048-3.

Haney M, Hill MN. Cannabis and Cannabinoids: From Synapse to Society. Neuropsychopharmacology. 2018 Jan;43(1):1-3. doi: 10.1038/npp.2017.255.

Busquets-Garcia A, Bains J, Marsicano G. CB(1) Receptor Signaling in the Brain: Extracting Specificity from Ubiquity. Neuropsychopharmacology. 2018 Jan;43(1):4-20. doi: 10.1038/npp.2017.206.

Meyer HC, Lee FS, Gee DG. The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development. Neuropsychopharmacology. 2018 Jan;43(1):21-33. doi: 10.1038/npp.2017.143.

Cooper ZD, Craft RM. Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. Neuropsychopharmacology. 2018 Jan;43(1):34-51. doi: 10.1038/npp.2017.140.

Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, Lichtman AH. The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology. 2018 Jan;43(1):52-79. doi: 10.1038/npp.2017.204.

Hill MN, Campolongo P, Yehuda R, Patel S. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. Neuropsychopharmacology. 2018 Jan;43(1):80-102. doi: 10.1038/npp.2017.162.

Wenzel JM, Cheer JF. Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling. Neuropsychopharmacology. 2018 Jan;43(1):103-115. doi: 10.1038/npp.2017.126.

Panlilio LV, Justinova Z. Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure. Neuropsychopharmacology. 2018 Jan;43(1):116-141. doi: 10.1038/npp.2017.193.

Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ(9)-Tetrahydrocannabinol. Neuropsychopharmacology. 2018 Jan;43(1):142-154. doi: 10.1038/npp.2017.209.

Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology. 2018 Jan;43(1):155-172. doi: 10.1038/npp.2017.130.

Brezing CA, Levin FR. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Neuropsychopharmacology. 2018 Jan;43(1):173-194. doi: 10.1038/npp.2017.212.

Hasin DS. US Epidemiology of Cannabis Use and Associated Problems. Neuropsychopharmacology. 2018 Jan;43(1):195-212. doi: 10.1038/npp.2017.198.

McLaughlin RJ. Toward a Translationally Relevant Preclinical Model of Cannabis Use. Neuropsychopharmacology. 2018 Jan;43(1):213. doi: 10.1038/npp.2017.191.

Haines-Saah RJ, Jenkins EK. Setting the Legal Age for Access to Cannabis in Canada: Bridging Neuroscience, Policy, and Prevention. Neuropsychopharmacology. 2018 Jan;43(1):213-214. doi: 10.1038/npp.2017.234.

Ware MA. Medical Cannabis Research: Issues and Priorities. Neuropsychopharmacology. 2018 Jan;43(1):214-215. doi: 10.1038/npp.2017.222.

Watts VJ. Selective Adenylyl Cyclase Type 1 Inhibitors as Potential Opioid Alternatives For Chronic Pain. Neuropsychopharmacology. 2018 Jan;43(1):215-216. doi: 10.1038/npp.2017.190.

Baumann MH, Pasternak GW. Novel Synthetic Opioids and Overdose Deaths: Tip of the Iceberg? Neuropsychopharmacology. 2018 Jan;43(1):216-217. doi: 10.1038/npp.2017.211.

Nummenmaa L, Karjalainen T. Opioidergic regulation of pain and pleasure in human social relationships. Neuropsychopharmacology. 2018 Jan;43(1):217-218. doi: 10.1038/npp.2017.200.

Zheng J, Lin JJ. Modulating Amygdala-Hippocampal Network Communication: A Potential Therapy for Neuropsychiatric Disorders. Neuropsychopharmacology. 2018 Jan;43(1):218-219. doi: 10.1038/npp.2017.201.

Bury LA, Wynshaw-Boris A. Modeling Non-Syndromic Autism with Human-Induced Pluripotent Stem Cells. Neuropsychopharmacology. 2018 Jan;43(1):219-220. doi: 10.1038/npp.2017.195.

Moeller FG, Cunningham KA. Innovative Therapeutic Intervention For Opioid Use Disorder. Neuropsychopharmacology. 2018 Jan;43(1):220-221. doi: 10.1038/npp.2017.192.

Kavalali ET, Monteggia LM. The Ketamine Metabolite 2R,6R-Hydroxynorketamine Blocks NMDA Receptors and Impacts Downstream Signaling Linked to Antidepressant Effects. Neuropsychopharmacology. 2018 Jan;43(1):221-222. doi: 10.1038/npp.2017.210.

Wagner MJ. Cognitive Signaling in Cerebellar Granule Cells. Neuropsychopharmacology. 2018 Jan;43(1):222-223. doi: 10.1038/npp.2017.186.

Caligiuri SP, Kenny PJ. The Promise of Genome Editing for Modeling Psychiatric Disorders. Neuropsychopharmacology. 2018 Jan;43(1):223-224. doi: 10.1038/npp.2017.197.

Golden SA, Shaham Y. Aggression Addiction and Relapse: A New Frontier in Psychiatry. Neuropsychopharmacology. 2018 Jan;43(1):224-225. doi: 10.1038/npp.2017.173.

Corcoran CM, Cecchi GA. Computational Approaches to Behavior Analysis in Psychiatry. Neuropsychopharmacology. 2018 Jan;43(1):225-226. doi: 10.1038/npp.2017.188.

Shekhar A, Thakur GA. Cannabinoid Receptor 1 Positive Allosteric Modulators for Posttraumatic Stress Disorder. Neuropsychopharmacology. 2018 Jan;43(1):226-227. doi: 10.1038/npp.2017.230.

Cattaneo A, Pariante CM. Integrating 'Omics' Approaches to Prioritize New Pathogenetic Mechanisms for Mental Disorders. Neuropsychopharmacology. 2018 Jan;43(1):227-228. doi: 10.1038/npp.2017.221.

Joyner MA, Gearhardt AN, Flagel SB. A Translational Model to Assess Sign-Tracking and Goal-Tracking Behavior in Children. Neuropsychopharmacology. 2018 Jan;43(1):228-229. doi: 10.1038/npp.2017.196.

Baytaş O, Morrow EM. The Role of Mitochondrial Glutamate Metabolism in Cognitive Development and Disease. Neuropsychopharmacology. 2018 Jan;43(1):229-230. doi: 10.1038/npp.2017.202.

Young JW, Light GA. Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap. Neuropsychopharmacology. 2018 Jan;43(1):230-231. doi: 10.1038/npp.2017.218.

Hasin DS, Sarvet AL, Cerdá M, Keyes KM, Stohl M, Galea S, Wall MM. US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013. JAMA Psychiatry. 2017;74(6):579-588. doi: 10.1001/jamapsychiatry.2017.0724.

Kaskie B, Ayyagari P, Milavetz G, Shane D, Arora K. The Increasing Use of Cannabis Among Older Americans: A Public Health Crisis or Viable Policy Alternative? Gerontologist. 2017;57(6):1166-1172. pii: gnw166. doi: 10.1093/geront/gnw166.

National Academies Press. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (2017). ISBN: 978-0-309-45304-2. DOI: 10.17226/24625

Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016 May;17(5):293-306. doi: 10.1038/nrn.2016.28.

AAA Foundation for Traffic Safety. An Evaluation of Data from Drivers Arrested for Driving Under the Influence in Relation to Per se Limits for Cannabis. May, 2016.

AAA Foundation for Traffic Safety. Prevalence of Marijuana Involvement in Fatal Crashes: Washington, 2010 - 2014. May, 2016.

Federation of State Medical Boards. Model Guidelines for the Recommendation of Marijuana in Patient Care. April, 2016.

World Health Organization (WHO). The health and social effects of nonmedical cannabis use. 2016.

Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction. 2016 Feb 16. doi: 10.1111/add.13347.

Piomelli D, Grant I. Medicinal Cannabis in California: an interview with Igor Grant, MD. Cannabis and Cannabinoid Research 1:1, 78–80, DOI: 10.1089/can.2016.29005.igr.

Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, McGue M, Raine A, Baker LA. Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proc Natl Acad Sci USA. 2016 Feb 2;113(5):E500-8. doi: 10.1073/pnas.1516648113.

Compton, R. P. & Berning, A. (2015, February). Drug and alcohol crash risk. (Traffic Safety Facts Research Note. DOT HS 812 117). Washington, DC: National Highway Traffic Safety Administration.

Weiland BJ, Thayer RE, Depue BE, Sabbineni A, Bryan AD, Hutchison KE. Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. J Neurosci. 2015 Jan 28;35(4):1505-12. doi: 10.1523/JNEUROSCI.2946-14.2015.

American Academy of Pediatrics, Policy Statement. The Impact of Marijuana Policies on Youth: Clinical, Research, and Legal Update. Pediatrics. 2015 Jan 26. pii: peds. 2014-4147.

American Academy of Pediatrics, Technical Report. The Impact of Marijuana Policies on Youth: Clinical, Research, and Legal Update. Pediatrics. 2015 Jan 26. pii: peds. 2014-4146.

Power RA, Verweij KJ, Zuhair M, Montgomery GW, Henders AK, Heath AC, Madden PA, Medland SE, Wray NR, Martin NG. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014 Nov;19(11):1201-4. doi: 10.1038/mp.2014.51.

Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Apr 29;82(17):1556-63.

Molina PE, Amedee AM, Lecapitaine NJ, Zabaleta J, Mohan M, Winsauer PJ, Vande Stouwe C, McGoey RR, Auten MW, Lamotte L, Chandra LC, Birke LL. Modulation of Gut-Specific Mechanisms by Chronic Δ9-Tetrahydrocannabinol Administration in Male Rhesus Macaques Infected with Simian Immunodeficiency Virus: A Systems Biology Analysis. AIDS Res Hum Retroviruses. 2014 Feb 7.

Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013 Dec;29(3):574-7. doi: 10.1016/j.yebeh.2013.08.037.

Sirven JI. Medical marijuana for epilepsy: Winds of change. Epilepsy Behav. 2013 Dec;29(3):435-6. doi: 10.1016/j.yebeh.2013.09.004.

Cooper ZD, Comer SD, Haney M. Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana In Daily Marijuana Smokers. Neuropsychopharmacology. 2013 Apr 22. doi: 10.1038/npp.2013.97.

Schier AR, Ribeiro NP, de Oliveira e Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr. 2012 Jun;34 Suppl 1:S104-10. English, Portuguese.

Abrams DA, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-Opioid Interaction in Chronic Pain. Clinical Pharmacology & Therapeutics (2011); 90 6, 844–851. doi:10.1038/clpt.2011.188.

California Medical Association. Cannabis and the Regulatory Void: Background Paper and Recommendations. (2011)

American Society of Addiction Medicine, President’s Action Committee on Medical Marijuana. The Role of the Physician in "Medical" Marijuana. Barthwell A., Baxter L., Cermak T., DuPont R., Kraus M., Levounis P. September 2010.

Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 10.1503/cmaj.091414. August 2010.

Center for Medicinal Cannabis Research: Report to the California Legislature (2010)

American Medical Association, Report 3 of the Council on Science and Public Health, Use of Cannabis for Medicinal Purposes (2009)

American College of Physicians, Position Paper: Supporting Research into the Therapeutic Role of Marijuana (2008)

Action Report: Medical Board of California, July 2004. California Physicians & Medical Marijuana: A Statement by the Medical Board of California -- May 7, 2004

National Institute on Drug Abuse, Conference Summary, 2001: Workshop on Clinical Consequences of Marijuana

Institute of Medicine Report, 2000: Marijuana As Medicine?: The Science Beyond the Controversy

Institute of Medicine Report, 1999: Marijuana and Medicine: Assessing the Science Base

The United Kingdom Parliament, House of Lords, Select Committee on Science & Technology, Ninth Report, November 4,1998, Cannabis: The Scientific & Medical Evidence

National Institutes of Health, Expert Panel Report, 1997: Workshop on the Medical Utility of Marijuana

The Canadian Consortium for the Investigation of Cannabinoids in Human Therapeutics (CCIC)
A Summary of Research Abstracts - updated monthly